Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies, GlaxoSmithKline Collaborate on MRD Testing

NEW YORK – Adaptive Biotechnologies and GlaxoSmithKline announced late Tuesday a collaboration to use Adaptive's ClonoSeq assay to assess minimal residual disease (MRD) across GSK's portfolio of hematology products.

Under the terms of the non-exclusive agreement, GSK may use the US Food and Drug Administration-cleared ClonoSeq test in its hematology clinical trials to generate data supporting the clinical value of monitoring MRD in the context of patient care. Adaptive will receive upfront and potential future regulatory milestone payments in certain geographies. Specific financial and other terms of the agreement were not disclosed.

"We are thrilled to collaborate with GSK to implement our leading MRD test across their groundbreaking hematology portfolio as a measure of treatment response and patient outcomes," Adaptive CEO and Cofounder Chad Robins, said in a statement. "MRD is increasingly used as an endpoint in clinical trials, and ClonoSeq has emerged as the premier test to reliably and accurately measure MRD to help advance novel therapies."

Adaptive's next-generation sequencing-based ClonoSeq test is cleared for use in MRD testing for chronic lymphocytic leukemia, multiple myeloma and B-cell acute lymphoblastic leukemia. In hematologic malignancies, it can be used to see if a patient is responding to treatment or if the cancer has returned.

The deal is the second portfolio-wide partnership related to MRD testing for Seattle-based Adaptive. In September 2019, the firm signed a similar deal with Amgen. Adaptive has also partnered with AbbVie and Genentech on MRD testing in clinical trials.

In August 2020, ClonoSeq received additional clearance from the FDA to detect and monitor MRD in blood or bone marrow from patients with CLL.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more